Globeflex Capital’s 10x Genomics TXG Stock Holding History

Globeflex Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,633	Closed	-$426K	–	511
2023 Q1	$426K	Buy	+7,633	New	+$356K	0.05%	271

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

Globeflex Capital's TXG Position: Q2 2023 in Review

Globeflex Capital sold out of 10x Genomics (TXG) in Q2 2023, closing a stake of 7,633 shares — an estimated $426K sold.

Globeflex Capital first reported a position in TXG in Q1 2023 and held it in 1 quarter. The position peaked at $426K in Q1 2023. 274 funds tracked by Wall St. Rank hold TXG as of Q2 2023.

Globeflex Capital reported no remaining 10x Genomics position as of Q2 2023 after selling out during the quarter.
Globeflex Capital sold 7,633 10x Genomics shares in Q2 2023, an estimated $426K.
Globeflex Capital first reported a position in 10x Genomics in Q1 2023 and held it in 1 quarter.
Globeflex Capital's 10x Genomics position peaked at $426K in Q1 2023.
274 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2023.

Based on Globeflex Capital's 13F filing for Q2 2023, filed 14 Aug 2023.